Progression of Unresected Intraductal Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-analysis

Choi, Sang Hyun; Park, Seong Ho; Kim, Kyung Won; Lee, Ja Youn; Lee, Sang Soo

doi:10.1016/j.cgh.2017.03.020

Cited by 79 publications

(64 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The model started with a 65-year-old patient as this can be seen as the average age of detection/diagnosis. 32 For a younger patient our analysis showed that a surgical approach, especially strategy I, can be a suitable option. We did not incorporate loss of productivity into our analysis, which we believe would have further strengthened a more active approach in a younger patient.…”

Section: Discussionmentioning

confidence: 90%

Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype

Aronsson

Ansari

Andersson

et al. 2018

HPB

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 90%

Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype

Aronsson

Ansari

Andersson

et al. 2018

HPB

View full text Add to dashboard Cite

show abstract

“…Often, both these types of dysplasia can be seen in the same lesion suggesting progression from low grade to high grade occurs in vivo. A LG dysplasia lesion has 8% chance of turning into IPMN associated carcinoma while a HG dysplasia lesion turns into IPMNC with 25% chance over 10 years [10]. Pancreatic cancer has poor survival rates which have improved only little in recent years even in developed countries.…”

Section: Discussionmentioning

confidence: 99%

Label-free serum proteomics and multivariate data analysis identifies biomarkers and expression trends that differentiate Intraductal papillary mucinous neoplasia from pancreatic adenocarcinoma and healthy controls

et al. 2019

View full text Add to dashboard Cite

Background: Intraductal Papillary Mucinous Neoplasia (IPMN) are potentially malignant cystic tumors of the pancreas. IPMN can progress from low to moderate to high grade dysplasia and further to IPMN associated carcinoma. Often the difference between benign and malignant nature of the IPMN is not clear preoperatively. We aim to elucidate molecular expression patterns of various grades of IPMN and pancreatic carcinoma. Additionally we suggest potential novel biomarkers to differentiate IPMN from healthy individuals and pancreatic carcinoma to enable early detection as well as help in differential diagnosis in future. Methods: We have performed retrospective label-free proteomic analysis of the serum samples from 44 patients with various grades of benign IPMN or IPMN associated carcinoma and 11 healthy controls. Proteomic data was further analyzed by various multivariate statistical methods. Four groups of samples (low-grade, high-grade IPMN, pancreatic carcinoma and age-and sex-matched healthy controls) were compared with ANOVA. Orthogonal projections to latent structures-discriminant analysis (OPLS-DA) modeling gave S-plot for feature selection. Stringently selected potential markers were further evaluated with ROC curve analysis and area under the curve was calculated. Differentially expressed proteins were used for pathway analysis. Linear trend analysis (Mann Kendall test) was used for identifying significant increasing or decreasing trends from healthy-low grade-high grade IPMN-pancreatic carcinoma.

show abstract

“…These imaging modalities will reveal an incidental pancreatic lesion in up to 45% of patients [1][2][3][4]. Many incidentally identified pancreatic cysts are IPMNs, a subset of which may be precursors of pancreatic adenocarcinoma (PDAC) [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Stratifying Intraductal Papillary Mucinous Neoplasms by Cyst Fluid Analysis: Present and Future

Hao

Takahashi

Snyder

et al. 2020

IJMS

View full text Add to dashboard Cite

A significant proportion of patients with intraductal papillary mucinous neoplasms (IPMNs) undergo surgical resection in order to prevent or treat pancreatic cancer at the risk of significant perioperative morbidity. Efforts have been made to stratify the potential risk of malignancy based on the clinical and radiographic features of IPMN to delineate which cysts warrant resection versus observation. An analysis of the cyst fluid obtained by preoperative endoscopic examination appears to be correlative of cyst type and risk, whereas serum markers and radiographic findings have not yet reached a level of sensitivity or specificity that proves they are clinically meaningful. In this review, we investigate the current cyst fluid analysis studies and present those that have shown promise in effectively stratifying high-risk versus low-risk lesions. While new cyst fluid markers continue to be identified, additional efforts in testing panels and marker composites in conjunction with clinical algorithms have also shown promise in distinguishing dysplasia and the risk of malignancy. These should be tested prospectively in order to determine their role in guiding the surveillance of low-risk lesions and to evaluate the new markers detected by proteomics and genetic sequencing.

show abstract

Progression of Unresected Intraductal Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-analysis

Cited by 79 publications

References 44 publications

Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype

Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype

Label-free serum proteomics and multivariate data analysis identifies biomarkers and expression trends that differentiate Intraductal papillary mucinous neoplasia from pancreatic adenocarcinoma and healthy controls

Stratifying Intraductal Papillary Mucinous Neoplasms by Cyst Fluid Analysis: Present and Future

Contact Info

Product

Resources

About